{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:17Z","timestamp":1777858337630,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>For abuse potential assessment, U.S. Food and Drug Administration (FDA) requests that new, brain-penetrating drugs are ideally compared with approved drugs that share the mechanism of action and are judged to have abuse liability by the Drug Enforcement Agency. For development of the dual orexin receptor antagonist (DORA) daridorexant, the FDA recommended conducting a rat drug discrimination paradigm against the approved, schedule IV, DORA suvorexant. Surprisingly, at suvorexant plasma levels up to three-fold the maximum concentration at the highest approved human dose, rats did not learn to discriminate the suvorexant stimulus from vehicle.<\/jats:p>","DOI":"10.1177\/02698811231211176","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T07:12:34Z","timestamp":1700464354000},"page":"1261-1264","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-6555","authenticated-orcid":false,"given":"Michel A","family":"Steiner","sequence":"first","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Toeroek-Schafroth","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland"},{"name":"Galapagos GmbH, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Dacome","sequence":"additional","affiliation":[{"name":"Aptuit Srl, An Evotec Company, Verona, Italy"},{"name":"No Longer Employed by Aptuit, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Tessari","sequence":"additional","affiliation":[{"name":"Aptuit Srl, An Evotec Company, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"bibr1-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.006"},{"key":"bibr2-02698811231211176","unstructured":"FDA (2014), Approval letter suvorexant. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204569Orig1s000Approv.pdf (accessed 13 August 2023)."},{"key":"bibr3-02698811231211176","unstructured":"FDA (2017), Guidance document on the assessment of abuse potential of drugs. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessment-abuse-potential-drugs (accessed 30 August 2023)."},{"key":"bibr4-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"bibr5-02698811231211176","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.22nr03385"},{"key":"bibr6-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.167"},{"key":"bibr7-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.224"},{"key":"bibr8-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241596"},{"key":"bibr9-02698811231211176","doi-asserted-by":"publisher","DOI":"10.3109\/01677063.2011.566953"},{"key":"bibr10-02698811231211176","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0650-4"},{"key":"bibr11-02698811231211176","first-page":"117","volume":"116","author":"Young R","year":"1991","journal-title":"NIDA Res Monogr"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231211176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811231211176","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231211176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:32Z","timestamp":1777507892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811231211176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/02698811231211176"],"URL":"https:\/\/doi.org\/10.1177\/02698811231211176","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}